Mauricio Z Baptista
@mzbaptista.bsky.social
MD, PhD, Medical Oncologist, interests #breastcancer #bcsm #gyncsm #GlobalOnc #Immunotherapy #medsky #oncsky
linkedin.com/in/mzbaptista
Views my own
🇧🇷🌎
linkedin.com/in/mzbaptista
Views my own
🇧🇷🌎
Reposted by Mauricio Z Baptista
Voting for the ASCO Election is now open. All eligible members are encouraged to cast their ballots: brnw.ch/21wXgpl
November 6, 2025 at 4:32 PM
Voting for the ASCO Election is now open. All eligible members are encouraged to cast their ballots: brnw.ch/21wXgpl
Reposted by Mauricio Z Baptista
In this short video, Dr. @jrgralow.bsky.social shares why finding the best dose of drug for each patient is important. Watch now and learn how you can get involved: tinyurl.com/6e36vvkh
September 29, 2025 at 5:14 PM
In this short video, Dr. @jrgralow.bsky.social shares why finding the best dose of drug for each patient is important. Watch now and learn how you can get involved: tinyurl.com/6e36vvkh
Reposted by Mauricio Z Baptista
Fun and energizing talk last week at the International Student House of DC. My talk: Beyond Borders: A Career in Global Oncology. The Power of Partnerships, Advocacy, and Collaboration. @ascocancer.bsky.social
September 18, 2025 at 10:55 PM
Fun and energizing talk last week at the International Student House of DC. My talk: Beyond Borders: A Career in Global Oncology. The Power of Partnerships, Advocacy, and Collaboration. @ascocancer.bsky.social
Reposted by Mauricio Z Baptista
Every day during #ASCO25, Dr. John Sweetenham will offer concise expert analysis on some of the day's top abstracts on the #ASCODailyNews Podcast. Listen to today's episode on Day 1 and check back daily at 4:30pm CT for more: dailynews.ascopubs.org/do/podcast-d... #oncsky
May 30, 2025 at 11:42 PM
Every day during #ASCO25, Dr. John Sweetenham will offer concise expert analysis on some of the day's top abstracts on the #ASCODailyNews Podcast. Listen to today's episode on Day 1 and check back daily at 4:30pm CT for more: dailynews.ascopubs.org/do/podcast-d... #oncsky
Reposted by Mauricio Z Baptista
Burnout among oncology and healthcare professionals is on the rise, but what can be done? The Cancer Network spoke with Dr. Eric Winer on ways to address burnout and improve well-being, incl findings published in our Journal of Clinical Oncology.
Workplace Burnout Among Oncologists Has Risen: What Can Be Done?
Results from a recent survey showed that 20% of oncologists planned to reduce their hours in the next 12 months, as workplace burnout among them has increased.
www.cancernetwork.com
May 9, 2025 at 2:04 PM
Burnout among oncology and healthcare professionals is on the rise, but what can be done? The Cancer Network spoke with Dr. Eric Winer on ways to address burnout and improve well-being, incl findings published in our Journal of Clinical Oncology.
Reposted by Mauricio Z Baptista
So excited to kick off the first episode of our new podcast: ASCO Education: By the Book with good friend and former #EdBook editor @drdonsdizon.bsky.social!
@ascocancer.bsky.social ascoeducation.libsyn.com/the-evolutio...
@ascocancer.bsky.social ascoeducation.libsyn.com/the-evolutio...
ASCO Education: The Evolution of the ASCO Educational Book and the Issues Shaping the Future of Oncology
On the inaugural episode of ASCO Education: By the Book, Dr. Nathan Pennell and Dr. Don Dizon share reflections on the evolution of the ASCO Educational Book, its global reach, and the role of its new...
ascoeducation.libsyn.com
April 14, 2025 at 2:46 PM
So excited to kick off the first episode of our new podcast: ASCO Education: By the Book with good friend and former #EdBook editor @drdonsdizon.bsky.social!
@ascocancer.bsky.social ascoeducation.libsyn.com/the-evolutio...
@ascocancer.bsky.social ascoeducation.libsyn.com/the-evolutio...
Reposted by Mauricio Z Baptista
Real-world risk of recurrence and treatment outcomes with adjuvant endocrine therapy in patients with stage II-III HR+/HER2- early breast cancer www.thebreastonline.com/article/S096...
Real-world risk of recurrence and treatment outcomes with adjuvant endocrine therapy in patients with stage II-III HR+/HER2- early breast cancer
Despite adjuvant endocrine therapy (ET), recurrence is still a concern for patients
with HR+/HER2- early breast cancer (EBC). We assessed recurrence risk in real-world
patients with stage II/III HR+/H...
www.thebreastonline.com
April 3, 2025 at 1:00 PM
Real-world risk of recurrence and treatment outcomes with adjuvant endocrine therapy in patients with stage II-III HR+/HER2- early breast cancer www.thebreastonline.com/article/S096...
Reposted by Mauricio Z Baptista
Nice piece in @cancertherapyadv.bsky.social about managing cancer care in the setting of natural disasters. @ascocancer.bsky.social
Experts explain how to prevent or reduce disruptions to #cancer care in the face of #naturaldisasters. With @jrgralow.bsky.social of @ascocancer.bsky.social, Matt Berkheiser of @mdanderson.bsky.social, Kelly Batista of @ufhealthcancer.bsky.social, Martin Palmeri & Tena Messer. shorturl.at/k9XpW
Natural Disasters and Cancer Care: How to Reduce Disruptions and Protect Patients
The recent wildfires in Los Angeles are just the latest in a series of natural disasters that have disrupted cancer care.
shorturl.at
March 19, 2025 at 9:54 PM
Nice piece in @cancertherapyadv.bsky.social about managing cancer care in the setting of natural disasters. @ascocancer.bsky.social
Reposted by Mauricio Z Baptista
Meredith Regan proposes framework using established criteria for pragmatic clinical trial design, then walks audience thru process using PREPEC. #masterclass #SGBCC2025
March 14, 2025 at 12:19 PM
Meredith Regan proposes framework using established criteria for pragmatic clinical trial design, then walks audience thru process using PREPEC. #masterclass #SGBCC2025
Reposted by Mauricio Z Baptista
Beyond ChatGPT and digital pathology algorithms, @jnkt.bsky.social reviews current and future states for deep learning artificial intelligence in breast oncology #SGBCC2025
March 13, 2025 at 3:23 PM
Beyond ChatGPT and digital pathology algorithms, @jnkt.bsky.social reviews current and future states for deep learning artificial intelligence in breast oncology #SGBCC2025
Reposted by Mauricio Z Baptista
In science, we expand our knowledge & change our thinking through peer-reviewed, evidence based publications—it is what separates science from, well, political power grabs evidently trying to stop science.
#FundScience #PublishScience #ShareScience
#FundScience #PublishScience #ShareScience
Pubmed being down really starts to make you realise how the ripple effects of the sabotage to science in the US affects the whole scientific community (not withstanding the awful impact on funding for colleagues)
March 2, 2025 at 11:14 AM
In science, we expand our knowledge & change our thinking through peer-reviewed, evidence based publications—it is what separates science from, well, political power grabs evidently trying to stop science.
#FundScience #PublishScience #ShareScience
#FundScience #PublishScience #ShareScience
Reposted by Mauricio Z Baptista
.@ascocancer.bsky.social engages in judicial and legislative advocacy to protect NIH funding: www.asco.org/news-initiat...
ASCO Engages in Judicial and Legislative Advocacy to Protect NIH Funding - ASCO
www.asco.org
February 24, 2025 at 2:50 PM
.@ascocancer.bsky.social engages in judicial and legislative advocacy to protect NIH funding: www.asco.org/news-initiat...
Reposted by Mauricio Z Baptista
What a great start to 2025 having our review on the role of hashtag#CDKs in human physiology and diseases just published in #Signal_Transduction_Targeted_Therapies!
Here is the link to the open access article 👇
rdcu.be/d6a4g
A big effort of the lab but we learnt a lot!
I hope you will enjoy it
Here is the link to the open access article 👇
rdcu.be/d6a4g
A big effort of the lab but we learnt a lot!
I hope you will enjoy it
Cyclin-dependent protein kinases and cell cycle regulation in biology and disease
Signal Transduction and Targeted Therapy - Cyclin-dependent protein kinases and cell cycle regulation in biology and disease
rdcu.be
January 14, 2025 at 8:33 PM
What a great start to 2025 having our review on the role of hashtag#CDKs in human physiology and diseases just published in #Signal_Transduction_Targeted_Therapies!
Here is the link to the open access article 👇
rdcu.be/d6a4g
A big effort of the lab but we learnt a lot!
I hope you will enjoy it
Here is the link to the open access article 👇
rdcu.be/d6a4g
A big effort of the lab but we learnt a lot!
I hope you will enjoy it
Reposted by Mauricio Z Baptista
The OncoAlert🚨 Network along with our partners
invite you to the #OncoAlertColloquium
REGISTER for FREE HERE👉 https://buff.ly/3CChgre
February 3-9, 2025 💯% Virtual& Interactive
Watch Our #BreastCancer Faculty @hoperugo.bsky.social 🇺🇸
Presenting on Advanced TNBC Year in Review
invite you to the #OncoAlertColloquium
REGISTER for FREE HERE👉 https://buff.ly/3CChgre
February 3-9, 2025 💯% Virtual& Interactive
Watch Our #BreastCancer Faculty @hoperugo.bsky.social 🇺🇸
Presenting on Advanced TNBC Year in Review
January 24, 2025 at 2:11 PM
The OncoAlert🚨 Network along with our partners
invite you to the #OncoAlertColloquium
REGISTER for FREE HERE👉 https://buff.ly/3CChgre
February 3-9, 2025 💯% Virtual& Interactive
Watch Our #BreastCancer Faculty @hoperugo.bsky.social 🇺🇸
Presenting on Advanced TNBC Year in Review
invite you to the #OncoAlertColloquium
REGISTER for FREE HERE👉 https://buff.ly/3CChgre
February 3-9, 2025 💯% Virtual& Interactive
Watch Our #BreastCancer Faculty @hoperugo.bsky.social 🇺🇸
Presenting on Advanced TNBC Year in Review
Reposted by Mauricio Z Baptista
🎉 MedNews Week Turns 3! 🎉
Earlier this month, MedNews Week celebrated its 3rd anniversary! 🥳 We are deeply grateful to our incredible Keynote Speakers for supporting our mission to advance global medical education and combat misinformation. 🌍📚
Earlier this month, MedNews Week celebrated its 3rd anniversary! 🥳 We are deeply grateful to our incredible Keynote Speakers for supporting our mission to advance global medical education and combat misinformation. 🌍📚
December 25, 2024 at 11:15 PM
🎉 MedNews Week Turns 3! 🎉
Earlier this month, MedNews Week celebrated its 3rd anniversary! 🥳 We are deeply grateful to our incredible Keynote Speakers for supporting our mission to advance global medical education and combat misinformation. 🌍📚
Earlier this month, MedNews Week celebrated its 3rd anniversary! 🥳 We are deeply grateful to our incredible Keynote Speakers for supporting our mission to advance global medical education and combat misinformation. 🌍📚
Reposted by Mauricio Z Baptista
Interesting new study looking at screening colonoscopy intervals and individual's risk profiles - >10 years may be optimal with lower risk
jamanetwork.com/journals/jam...
jamanetwork.com/journals/jam...
Negative Screening Results and Colorectal Cancer
This cohort study compares the long-term risk of colorectal cancer incidence and mortality among individuals receiving a negative colonoscopy screening result with those not undergoing endoscopy.
jamanetwork.com
December 20, 2024 at 2:56 PM
Interesting new study looking at screening colonoscopy intervals and individual's risk profiles - >10 years may be optimal with lower risk
jamanetwork.com/journals/jam...
jamanetwork.com/journals/jam...
Reposted by Mauricio Z Baptista
OUR COMPLETE #SABCS24 🚨Newsletter IS OUT
REGISTER at oncoalert360.com OR buff.ly/48Xpgz0
This Includes all of OUR TOP pick of TRIALS presented during these last 4 days in San Antonio & Video Interviews from our Collaborators at @vjoncology.bsky.social and high5md
REGISTER at oncoalert360.com OR buff.ly/48Xpgz0
This Includes all of OUR TOP pick of TRIALS presented during these last 4 days in San Antonio & Video Interviews from our Collaborators at @vjoncology.bsky.social and high5md
December 16, 2024 at 5:00 PM
OUR COMPLETE #SABCS24 🚨Newsletter IS OUT
REGISTER at oncoalert360.com OR buff.ly/48Xpgz0
This Includes all of OUR TOP pick of TRIALS presented during these last 4 days in San Antonio & Video Interviews from our Collaborators at @vjoncology.bsky.social and high5md
REGISTER at oncoalert360.com OR buff.ly/48Xpgz0
This Includes all of OUR TOP pick of TRIALS presented during these last 4 days in San Antonio & Video Interviews from our Collaborators at @vjoncology.bsky.social and high5md
Reposted by Mauricio Z Baptista
📣 ASCO is now here 🦋!
@ascocancer.bsky.social
@ascopost.bsky.social
#OncSky #AcademicSky #MedSky #Oncology #CancerResearch
@oncoalert.bsky.social
@oncodaily.bsky.social
@onclive.bsky.social
@ascocancer.bsky.social
@ascopost.bsky.social
#OncSky #AcademicSky #MedSky #Oncology #CancerResearch
@oncoalert.bsky.social
@oncodaily.bsky.social
@onclive.bsky.social
December 14, 2024 at 12:06 PM
Reposted by Mauricio Z Baptista
The OncoAlert 🚨Newsletter NOW OUT Covering September November 28-Dec 5, 2024
REGISTER AT www.OncoAlert360.com OR https://buff.ly/48Xpgz0
✅FDA Approves Duvalumab in #SCLC 🫁🇺🇸
✅FDA ACCELERATED APPROVAL TO
ZENOCUTUZUMAB-ZBCO IN #NSCLC 🫁
✅Lung adenocarcinomas with mucinous & more
REGISTER AT www.OncoAlert360.com OR https://buff.ly/48Xpgz0
✅FDA Approves Duvalumab in #SCLC 🫁🇺🇸
✅FDA ACCELERATED APPROVAL TO
ZENOCUTUZUMAB-ZBCO IN #NSCLC 🫁
✅Lung adenocarcinomas with mucinous & more
December 5, 2024 at 2:40 PM
The OncoAlert 🚨Newsletter NOW OUT Covering September November 28-Dec 5, 2024
REGISTER AT www.OncoAlert360.com OR https://buff.ly/48Xpgz0
✅FDA Approves Duvalumab in #SCLC 🫁🇺🇸
✅FDA ACCELERATED APPROVAL TO
ZENOCUTUZUMAB-ZBCO IN #NSCLC 🫁
✅Lung adenocarcinomas with mucinous & more
REGISTER AT www.OncoAlert360.com OR https://buff.ly/48Xpgz0
✅FDA Approves Duvalumab in #SCLC 🫁🇺🇸
✅FDA ACCELERATED APPROVAL TO
ZENOCUTUZUMAB-ZBCO IN #NSCLC 🫁
✅Lung adenocarcinomas with mucinous & more
Reposted by Mauricio Z Baptista
Good info here from CA: A Cancer Journal for Clinicians. Content is free, year round!
Happy holidays as we buckle in for a tumultuous few years.
Happy holidays as we buckle in for a tumultuous few years.
As December begins, people impacted by cancer may wish to take advantage of evidence-based advice for physical activity. Check out this free #PatientPage from the ACS's flagship journal CA for tips on nutrition and exercise: acsjournals.onlinelibrary.wiley.com/doi/10.3322/... #OncSky
December 3, 2024 at 1:53 PM
Good info here from CA: A Cancer Journal for Clinicians. Content is free, year round!
Happy holidays as we buckle in for a tumultuous few years.
Happy holidays as we buckle in for a tumultuous few years.
Reposted by Mauricio Z Baptista
SONIA trial - Pts with ER+ breast cancer beginning treatment in the metastatic setting randomized to 1st line vs 2nd line use of CDK4/6 inhibitor (+ endocrine therapy). No sig difference in PFS.
www.nature.com/articles/s41...
www.nature.com/articles/s41...
Early versus deferred use of CDK4/6 inhibitors in advanced breast cancer - Nature
The phase 3 SONIA trial challenges the benefits of using cyclin-dependent kinase 4 and 6 inhibitors as a first-line compared with second-line treatment.
www.nature.com
November 29, 2024 at 6:16 PM
SONIA trial - Pts with ER+ breast cancer beginning treatment in the metastatic setting randomized to 1st line vs 2nd line use of CDK4/6 inhibitor (+ endocrine therapy). No sig difference in PFS.
www.nature.com/articles/s41...
www.nature.com/articles/s41...
Reposted by Mauricio Z Baptista
Thanks @tmprowell.bsky.social
Will take this off social and send to our fellows. Such a great opportunity. it cannot live in the sky alone.
Will take this off social and send to our fellows. Such a great opportunity. it cannot live in the sky alone.
Link for more info & to access FDA-ASCO Fellows’ Day Workshop application is here: asco.smapply.org/prog/Februar....
Apply by 12/4/24. Hope to see some of you in person or on Zoom for a day of #regulatory science #MedEd, #OncSky! 😃
#MedSky #healthpolicy #mentorship #OncoAlert
Apply by 12/4/24. Hope to see some of you in person or on Zoom for a day of #regulatory science #MedEd, #OncSky! 😃
#MedSky #healthpolicy #mentorship #OncoAlert
February 2025 FDA/ASCO Fellows' Day Workshop - Application Portal
asco.smapply.org
November 27, 2024 at 2:27 PM
Thanks @tmprowell.bsky.social
Will take this off social and send to our fellows. Such a great opportunity. it cannot live in the sky alone.
Will take this off social and send to our fellows. Such a great opportunity. it cannot live in the sky alone.
Reposted by Mauricio Z Baptista
Now in JNCI “Pts w stage 1 & 2 breast cancer have excellent prognosis, yet account for >60% breast cancer–specific death due to large #. To ⬇️ breast cancer death, strategies neededed to identify,treat pts w/early stage BC w/ risk for recurrence” @oncoalert.bsky.social
doi.org/10.1093/jnci...
doi.org/10.1093/jnci...
Trends in breast cancer–specific death by clinical stage at diagnoses between 2000 and 2017
AbstractBackground. Approximately 40 000 individuals die from metastatic breast cancer each year. We examined what fractions of annual breast cancer–specif
doi.org
November 24, 2024 at 12:47 PM
Now in JNCI “Pts w stage 1 & 2 breast cancer have excellent prognosis, yet account for >60% breast cancer–specific death due to large #. To ⬇️ breast cancer death, strategies neededed to identify,treat pts w/early stage BC w/ risk for recurrence” @oncoalert.bsky.social
doi.org/10.1093/jnci...
doi.org/10.1093/jnci...